human
coronavirus
eg
hcov
caus
mild
upper
respiratori
tract
diseas
except
occasion
immunocompromis
host
howev
novel
coronavirus
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
recent
identifi
middl
east
respiratori
syndrom
coronaviru
merscov
may
caus
seriou
viral
pneumon
lead
hospit
death
coronavirus
larg
lipidenvelop
positivesens
singlestrand
rna
virus
viral
genom
analys
reveal
sarscov
merscov
group
b
group
c
betacoronaviru
respect
close
relat
coronavirus
found
bat
intermedi
mammalian
host
civet
cat
implic
sarscov
adapt
human
transmiss
host
identifi
merscov
coronavirus
encod
surfac
spike
glycoprotein
protein
attach
viru
host
cell
determin
host
rang
tropism
target
neutral
antibodi
shown
sarscov
use
human
angiotensinconvert
enzym
aceii
primari
cellular
receptor
human
ctype
lectin
dclsign
also
implic
altern
receptor
merscov
shown
bind
dipeptidyl
peptidas
also
call
interspeciesconserv
protein
found
surfac
sever
cell
type
includ
noncili
cell
human
airway
interact
may
explain
broad
host
rang
abil
caus
crossspeci
zoonot
transmiss
vaccin
avail
present
coronavirus
epidemiolog
diseas
transmiss
sarscov
emerg
southern
china
guangdong
provinc
februari
first
victim
direct
contact
live
anim
either
wet
market
restaur
sell
anim
winter
food
diseas
quickli
spread
hong
kong
within
week
intern
air
travel
reach
vietnam
singapor
taiwan
canada
juli
countri
affect
result
confirm
infect
death
mathemat
model
earli
phase
outbreak
estim
basic
reproduct
number
r
sarscov
rang
primari
mode
transmiss
via
respiratori
droplet
two
key
epidemiolog
featur
sar
frequent
nosocomi
outbreak
superspread
event
exacerb
transmiss
notabl
sar
victim
health
care
worker
suggest
viral
replic
peak
sar
patient
time
hospit
symptom
worsen
see
later
discuss
transmiss
facilit
close
bed
proxim
applic
aerosolgener
procedur
eg
intub
resuscit
devic
eg
continu
posit
airway
pressur
biphas
posit
airway
pressur
bipap
treatment
exampl
nebul
bronchodil
sar
patient
result
major
hospit
outbreak
involv
inpati
doctor
nurs
alli
health
worker
medic
student
work
medic
ward
subsequ
studi
indic
attack
rate
hospit
set
exampl
commun
superspread
event
involv
resid
occur
privat
hous
estat
amoy
garden
hong
kong
dri
ushap
bathroom
floor
drain
backflow
contamin
sewag
sar
patient
diarrhea
coupl
toilet
exhaust
fan
might
creat
infecti
aerosol
move
upward
warm
air
shaft
build
comput
fluiddynam
model
suggest
possibl
dispers
wind
flow
caus
longrang
transmiss
nearbi
build
evid
suggest
sar
could
opportunist
airborn
appropri
precaut
prevent
airborn
transmiss
implement
health
care
set
particularli
respiratori
procedur
devic
use
notabl
laboratoryrel
sar
case
occur
sinc
epidem
highlight
import
laboratori
safeti
handl
contagi
viral
pathogen
merscov
emerg
middl
east
june
total
peopl
saudi
arabia
qatar
jordan
unit
arab
emir
unit
kingdom
confirm
infect
caus
viru
epidemiolog
investig
far
reveal
sporad
transmiss
diseas
zoonot
transmiss
also
implic
even
though
case
report
histori
direct
anim
contact
unknown
whether
low
level
viru
circul
asymptomat
human
carrier
anim
reservoir
allow
multipl
introduct
human
base
report
famili
hospit
cluster
thought
humantohuman
transmiss
possibl
pathogenesi
human
preexist
immun
novel
coronavirus
sarscov
merscov
shown
abil
evad
innat
host
defens
eg
type
interferon
respons
relat
mechan
replic
effici
host
tissu
sarscov
respiratori
intestin
tract
cell
merscov
respiratori
intestin
kidney
cell
besid
lytic
cell
damag
uncontrol
replic
sarscov
lead
unab
inflammatori
cytokin
activ
eg
interleukin
il
monocyt
chemotact
interferoninduc
monokin
induc
interferonginduc
protein
commonli
known
cytokin
storm
implic
develop
progress
pneumon
diffus
alveolar
damag
acut
respiratori
distress
syndrom
ard
hemophagocyt
syndrom
clinic
respiratori
tract
viral
load
peak
around
day
subsequ
decreas
high
viral
load
slow
viral
clearanc
associ
progress
diseas
fatal
outcom
highlevel
viremia
intestin
tract
involv
also
predict
advers
outcom
littl
known
pathogenesi
merscov
macaqu
model
shown
activ
viral
replic
lung
tissu
caus
local
widespread
lesion
clinic
ill
start
decreas
week
clinic
manifest
diseas
cours
sar
describ
triphas
ill
typic
incub
period
day
rang
day
virem
phase
patient
experienc
fever
chill
rigor
partial
subsid
day
howev
case
follow
resurg
fever
cough
short
breath
hyperimmun
pneumonia
phase
chest
radiograph
first
show
patchi
consolid
groundglass
chang
rapidli
progress
next
day
involv
multipl
lobe
fig
certain
case
find
comput
tomographi
scan
thorax
close
resembl
bronchiol
obliteran
organ
pneumonia
eg
peripher
airspac
consolid
laboratori
featur
includ
lymphopenia
thrombocytopenia
increas
transaminas
creatinin
kinas
lactat
dehydrogenas
end
second
week
around
day
patient
deterior
develop
refractori
respiratori
failur
ard
pulmonari
destruct
phase
patient
develop
profus
diarrhea
contain
highli
viral
pneumonia
infecti
viru
particl
nevertheless
renal
failur
rare
substanti
proport
intub
mechan
ventil
patient
develop
bacteri
superinfect
eg
methicillinresist
staphylococcu
aureu
develop
complic
pneumothorax
pneumomediastinum
children
typic
mild
diseas
cours
rare
fatal
overal
death
rate
howev
agestratifi
case
fatal
rate
follow
less
year
less
year
year
greater
year
greater
preliminari
data
indic
clinic
manifest
merscov
infect
close
mimic
sar
patient
develop
short
breath
progress
pneumonia
week
symptom
onset
symptom
associ
multipl
patchi
consolid
groundglass
chang
chest
imag
laboratori
evid
lymphopenia
increas
liver
enzym
level
strikingli
mani
patient
develop
acut
renal
failur
clear
explan
patient
confirm
merscov
infect
develop
critic
ill
requir
admiss
intens
care
unit
icu
thu
far
patient
die
despit
maxim
support
treatment
earli
case
recognit
novel
infect
requir
high
index
suspicion
combin
detail
clinic
epidemiolog
assess
base
experi
sar
world
health
organ
recommend
laboratori
test
merscov
indic
patient
pneumonia
otherwis
unexplain
histori
travel
affect
area
test
also
consid
direct
contact
anoth
sick
individu
case
cluster
unexplain
pneumonia
health
care
worker
involv
prompt
isol
suspici
case
may
greatli
assist
infect
control
prevent
hospit
outbreak
revers
transcriptas
polymeras
chain
reaction
rtpcr
test
choic
coronaviru
infect
sarscov
combin
upper
respiratori
nasal
pharyng
nasopharyng
lower
respiratori
higher
yield
higher
viral
level
eg
sputum
tracheal
aspir
bronchial
alveolar
lavag
blood
fecal
specimen
requir
maxim
chanc
detect
plasma
rtpcr
may
detect
viremia
earli
day
symptom
onset
shown
prognost
valu
singl
neg
test
upper
respiratori
specimen
may
insuffici
rule
diagnosi
viru
cultur
may
provid
confirm
slow
assist
clinic
manag
need
perform
biosafeti
level
facil
serolog
diagnosi
larg
retrospect
may
use
epidemiolog
surveil
purpos
optim
clinic
specimen
merscov
test
uncertain
evid
suggest
better
yield
lower
respiratori
specimen
given
divers
period
emerg
novel
coronavirus
may
extrem
challeng
detect
clinician
consult
local
guidelin
determin
refer
case
coronaviru
test
special
refer
laboratori
eg
pancoronaviru
rtpcr
specif
sarscov
merscov
rtpcr
establish
therapi
coronaviru
infect
sar
outbreak
rang
agent
use
patient
efficaci
question
ribavirin
although
shown
activ
vitro
seem
provid
clinic
benefit
case
progress
despit
treatment
lopinavirritonavir
proteas
inhibitor
use
treat
human
immunodefici
viru
hiv
aid
evid
vitro
activ
sarscov
given
patient
hong
kong
associ
viral
load
reduct
fewer
case
ard
fewer
death
howev
studi
uncontrol
convalesc
plasma
obtain
recov
individu
contain
neutral
antibodi
also
use
studi
patient
receiv
therapi
better
surviv
vs
discharg
rate
vs
compar
control
form
treatment
also
use
fulmin
case
influenza
appar
success
subsequ
vitro
anim
ferret
hamster
macaqu
studi
shown
monoclon
antibodi
target
protein
may
provid
neutral
activ
sarscov
result
viral
load
reduct
resolut
lung
lesion
howev
clinic
data
avail
sever
vitro
anim
mice
macaqu
studi
consist
shown
type
interferon
given
prophylact
shortli
exposur
may
protect
sar
human
shown
interferona
given
within
day
ill
may
result
lower
rate
intub
vs
death
vs
howev
studi
small
vs
patient
confound
corticosteroid
use
preliminari
data
shown
type
type
iii
interferon
vitro
activ
merscov
observ
may
deserv
investig
publish
data
antibodi
therapi
approach
may
also
use
potenti
treatment
test
anim
model
includ
short
interf
rna
sirna
proteasom
inhibitor
prophylact
tolllik
receptor
agonist
administr
immunomodul
system
corticosteroid
therapi
perhap
controversi
area
sar
manag
tabl
although
favor
clinic
radiolog
respons
report
control
data
lack
random
placebocontrol
studi
perform
earli
corticosteroid
treatment
within
first
day
shown
delay
viral
clearanc
metabol
side
effect
bacteri
fungal
superinfect
avascular
osteonecrosi
even
acut
psychosi
report
systemat
review
conclud
corticosteroid
treatment
associ
definit
benefit
potenti
harm
similar
advers
viral
pneumonia
effect
report
sever
influenza
notabl
increas
mortal
also
found
unclear
whether
lower
dose
delay
treatment
viral
replic
begun
subsid
reduc
harm
current
recommend
corticosteroid
limit
sar
case
refractori
septic
shock
given
low
dose
eg
hydrocortison
mg
everi
hour
similar
recommend
made
merscov
infect
respiratori
syncyti
viru
rsv
envelop
singlestrand
rna
paramyxoviru
includ
major
group
b
consist
genotyp
rsv
genom
encod
nonstructur
structur
protein
includ
f
fusion
g
attach
glycoprotein
viral
envelop
antibodi
f
g
protein
neutral
shown
confer
protect
rsv
infect
anim
model
target
like
import
develop
antivir
agent
vaccin
immun
primari
infect
gener
occur
year
age
partial
shortliv
thu
reinfect
occur
throughout
life
low
serum
neutral
antibodi
level
adult
predict
infect
risk
diseas
sever
although
immunolog
mechan
eg
cytokin
respons
implic
pathogenesi
emerg
evid
suggest
uncontrol
viral
replic
indic
high
viral
load
drive
diseas
manifest
lead
sever
outcom
find
provid
import
rational
approach
antivir
drug
develop
rsv
rsv
known
import
caus
lower
respiratori
tract
infect
infant
young
children
eg
acut
bronchiol
wheezi
attack
result
hospit
death
yet
impact
adult
appreci
recent
year
estim
rsv
infect
adult
annual
although
infect
mild
increas
evid
suggest
sever
lower
respiratori
tract
infect
occur
especi
among
older
adult
eg
year
underli
condit
eg
chronic
lung
diseas
chronic
cardiovascular
diseas
rsv
may
account
communityacquir
pneumonia
hospit
admiss
acut
cardiorespiratori
diseas
excess
death
among
adult
season
peak
outbreak
among
nurs
home
resid
like
common
underrecogn
diseas
burden
rsv
shown
approach
season
influenza
patient
tabl
controversi
around
use
corticosteroid
therapi
sar
clinic
radiolog
respons
observ
suppress
inflammatori
cytokin
metabol
complic
hyperglycemia
hypertens
hypokalemia
increas
bacteri
superinfect
avascular
osteonecrosi
incid
low
total
prednisolon
dose
g
reduc
viral
clearanc
other
eg
acut
psychosi
data
ref
lee
qureshi
profoundli
immunosuppress
hematopoiet
stem
cell
transplant
hsct
recipi
particularli
high
risk
sever
rsv
infect
rapidli
fatal
clinic
manifest
rsv
infect
adult
divers
mainli
determin
host
factor
underli
chronic
medic
condit
degre
immunosuppress
healthi
young
adult
rsv
may
caus
selflimit
upper
respiratori
ill
profoundli
immunosuppress
progress
lower
respiratori
tract
diseas
occur
result
fulmin
pneumon
high
mortal
older
adult
hospit
rsv
infect
may
present
fever
cough
sputum
product
wheez
dyspnea
although
wheez
dyspnea
may
common
rsv
magnitud
fever
sometim
lower
find
could
reliabl
differenti
influenza
radiograph
case
show
activ
pneumon
chang
consolid
groundglass
opac
remaind
may
show
evid
congest
heart
failur
featur
underli
chronic
lung
condit
typic
pneumon
chang
small
patchi
unilater
disproport
degre
hypoxemia
detect
patient
diffus
interstiti
infiltr
pattern
rare
overal
patient
hospit
rsv
develop
sever
lower
respiratori
complic
includ
pneumonia
acut
bronchiti
exacerb
chronic
obstruct
pulmonari
diseas
copd
asthma
cardiovascular
complic
congest
heart
failur
acut
coronari
syndrom
bacteri
superinfect
occur
case
patient
requir
ventilatori
support
invasivenoninvas
overal
mortal
approxim
late
death
might
occur
result
multipl
cardiorespiratori
complic
exacerb
underli
medic
condit
studi
shown
morbid
mortal
rsv
infect
adult
actual
similar
season
influenza
diagnosi
rsv
infect
clinic
indistinguish
viral
respiratori
infect
diagnosi
requir
laboratori
test
commonli
nasopharyng
specimen
use
patient
requir
intub
lower
respiratori
tract
specimen
tracheal
aspir
obtain
gold
standard
diagnosi
rtpcr
rel
eas
speed
type
test
antigen
assay
eg
enzym
immunoassay
cultur
lower
sensit
might
relat
lower
viral
load
adult
neg
antigen
assay
result
use
rule
rsv
infect
serolog
detect
rsvspecif
igg
antibodi
may
also
assist
diagnosi
avail
use
combin
rtpcr
maxim
yield
present
establish
antivir
therapi
vaccin
avail
rsv
immunocompromis
adult
ribavirin
aerosol
system
administr
palivizumab
rsvspecif
monoclon
antibodi
direct
f
glycoprotein
use
treat
rsv
infect
aim
reduc
progress
lower
respiratori
diseas
death
howev
control
data
lack
anim
model
palivizumab
shown
reduc
viral
titer
replic
pulmonari
tissu
random
clinic
trial
palivizumab
given
prophylact
young
highrisk
children
shown
reduc
hospit
relat
viral
pneumonia
rsv
infect
current
known
whether
approach
appli
older
adult
new
antivir
agent
eg
fusion
protein
inhibitor
sirna
newer
gener
antibodi
therapi
activ
research
system
corticosteroid
commonli
use
treat
wheez
exacerb
copdasthma
adult
includ
trigger
viral
infect
convers
random
control
trial
corticosteroid
therapi
young
children
rsv
infect
reveal
lack
clinic
benefit
inconsist
control
inflammatori
cytokin
respons
recent
studi
corticosteroid
adult
report
viru
control
seem
unaffect
humor
immun
rsv
diminish
suggest
decis
treat
rsv
patient
corticosteroid
weigh
potenti
risk
eg
bacteri
superinfect
limit
short
cours
use
high
rate
secondari
infect
prudent
test
treat
bacteri
pathogen
accord
local
resist
profil
addit
streptococcu
pneumonia
hemophilia
influenza
pseudomona
aeruginosa
gramneg
bacilli
may
need
consid
patient
underli
chronic
lung
diseas
hospit
set
rsv
may
spread
via
contact
eg
hand
via
fomit
droplet
appropri
infect
control
measur
hand
wash
use
surgic
mask
health
care
worker
infect
patient
implement
rsv
particl
detect
air
sampl
health
care
facil
suggest
airborn
transmiss
nelson
lee
experienc
rsv
outbreak
relat
use
bipap
ventil
unpublish
suggest
appropri
isol
precaut
aerosolgener
procedur
devic
use
adenovirus
mediums
dna
virus
attach
host
cell
coxsacki
b
virusadenoviru
receptor
variat
tissu
tropism
individu
adenoviru
speci
serotyp
may
attribut
differenti
receptor
express
bind
altern
receptor
follow
endocytosi
nuclear
local
earli
gene
express
inhibit
variou
host
immun
respons
initi
viral
replic
wherea
late
gene
express
direct
viral
assembl
releas
host
cell
lysi
human
adenovirus
anim
reservoir
infect
speci
nonhuman
adenovirus
infect
speci
caus
zoonot
diseas
tradit
classif
human
adenovirus
complex
includ
least
serotyp
adenovirus
also
divid
speci
ag
base
variou
biolog
biochem
characterist
speci
includ
serotyp
serotyp
includ
multipl
genotyp
although
strict
correl
speci
serotyp
diseas
manifest
possibl
make
certain
gener
exampl
respiratori
diseas
caus
speci
b
c
e
wherea
speci
f
caus
gastroenter
comprehens
review
serotyp
associ
diseas
recent
publish
adenovirus
lack
outer
envelop
rel
resist
dessic
low
ph
gastric
biliari
secret
predomin
rout
transmiss
includ
direct
contact
aerosol
droplet
militari
set
fecalor
spread
among
children
prolong
shed
stool
exposur
infect
fomit
blood
tissu
incub
period
vari
day
week
adenovirus
may
clear
may
caus
longstand
asymptomat
infect
lymphoid
mucos
cell
particularli
children
case
adenovirus
may
becom
latent
retain
potenti
undergo
endogen
reactiv
later
time
point
highli
immunesuppress
host
combin
innat
adapt
immun
respons
requir
control
prevent
adenoviru
infect
vivo
innat
antivir
immun
mediat
natur
killer
nk
cell
neutrophil
monocytesmacrophag
capabl
directli
kill
infect
cell
secret
inflammatori
cytokin
chemokin
recruit
addit
effector
cell
type
optim
adapt
immun
includ
neutral
antibodi
product
antigenspecif
b
cell
well
gener
expans
lymphocyt
capabl
elimin
infect
host
cell
adenovirus
dedic
signific
portion
genom
subvers
host
defens
mechan
ensur
infect
cell
surviv
facilit
viru
transmiss
vivo
epidemiolog
almost
case
adenovir
infect
mild
selflimit
episod
occur
childhood
estim
caus
febril
ill
pediatr
popul
compar
children
sever
adenovir
diseas
much
less
common
adult
make
time
diagnosi
critic
ill
patient
quit
challeng
possibl
epidemiolog
clue
adenoviru
infect
includ
cluster
febril
pharyng
conjunct
respiratori
diseas
individu
live
close
quarter
includ
daycar
center
chronic
care
facil
militari
barrack
anoth
clue
simultan
presenc
circul
adenovir
isol
commun
particularli
summer
autumn
month
influenza
less
common
sever
report
militari
train
center
shown
serotyp
may
associ
sever
diseas
result
greater
virul
transmiss
prompt
frequent
outbreak
begin
affect
militari
recruit
entericco
live
oral
vaccin
serotyp
introduc
success
diminish
acut
respiratori
diseas
immun
progress
stop
follow
resurg
epidem
diseas
caus
vaccin
serotyp
global
epidemiolog
adenoviru
infect
healthi
popul
includ
novel
genom
type
shown
caus
sever
fatal
diseas
sever
civilian
militari
outbreak
north
america
close
relat
endem
strain
china
south
america
similarli
virul
serotyp
adenoviru
strain
previous
observ
unit
state
recent
shown
caus
sever
fatal
adenoviru
diseas
children
adult
militari
recruit
adenoviru
infect
also
import
emerg
pathogen
among
hsct
recipi
incid
vari
accord
transplant
regimen
age
studi
popul
diagnost
test
strategi
rel
littl
known
incid
adenoviru
infect
among
adult
solidorgan
transplant
recipi
howev
plasma
dna
detect
case
prospect
surveil
studi
transplant
recipi
asymptomat
time
adenoviru
detect
recov
spontan
incid
adenoviru
patient
hiv
infect
undergo
cancer
chemotherapi
congenit
immunodefici
comprehens
review
civilian
set
sever
adenovir
diseas
extrem
unusu
healthi
adult
intact
immun
exampl
case
potenti
lifethreaten
adenovir
pneumonia
publish
sinc
addit
case
report
analyz
recent
seri
twothird
patient
male
mean
age
year
overal
mortal
rate
clinic
radiolog
featur
sever
adenovir
diseas
gener
nonspecif
could
mimic
bacteri
sepsi
although
presenc
conjunct
diarrhea
serv
potenti
diagnost
clue
varieti
serotyp
document
caus
sporad
case
sever
civilian
fatal
militari
adenovir
pneumonia
healthi
adult
although
relationship
genotyp
virul
comprehens
investig
largest
report
outbreak
occur
mental
health
center
caus
unusu
adenoviru
serotyp
associ
diseas
among
immunocompromis
patient
outbreak
affect
individu
present
fever
cough
associ
diffus
interstiti
dens
unilater
pulmonari
infiltr
distinguish
clinic
featur
evid
howev
sever
instanc
develop
mild
leukopenia
observ
six
infect
case
requir
icu
admiss
requir
intub
develop
ard
septic
shock
patient
recov
except
individu
chronic
renal
insuffici
requir
prolong
intub
die
month
admiss
typic
patholog
find
fatal
case
adenovir
pneumonia
includ
sever
necrot
bronchiol
fibrin
obstruct
interstiti
inflamm
hyalin
membran
line
characterist
alveolar
smudg
cell
larg
round
nucleu
contain
basophil
inclus
surround
halo
highli
immunesuppress
host
suscept
adenoviru
infect
variou
organ
system
brain
heart
lung
liver
intestin
kidney
pancrea
bladder
box
may
go
exhibit
spectrum
diseas
sever
influenc
age
underli
diseas
clinic
intervent
viru
serotyp
asymptomat
clinic
evid
diseas
occur
mainli
via
de
novo
viru
acquisit
reactiv
latent
infect
host
minor
case
attribut
donorderiv
infect
stem
cell
transplant
case
possibl
determin
exact
mechan
adenoviru
infect
clinic
ill
associ
coinfect
multipl
viral
serotyp
also
frequent
immunesuppress
host
compar
suscept
individu
develop
extrem
sensit
molecular
techniqu
quantit
realtim
pcr
systemat
screen
protocol
led
greater
recognit
adenoviru
infect
hsct
recipi
infect
rate
report
literatur
vari
wide
like
due
differ
diagnost
approach
host
factor
condit
regimen
thu
standard
detect
method
requir
definit
quantifi
incid
diseas
patient
popul
gener
pediatr
stem
cell
transplant
recipi
much
like
develop
adenoviru
infect
compar
adult
limit
natur
exposur
transplant
lack
speci
crossreact
cell
adenovir
infect
detect
first
day
transplant
although
median
time
detect
much
shorter
children
day
compar
adult
day
sever
risk
factor
adenovir
infect
box
diseas
box
transplant
reflect
state
profound
host
immun
defici
identifi
adenovir
infect
may
caus
subclin
viremia
singl
organ
system
dysfunct
interstiti
pneumon
cholangiohepat
hemorrhag
cystiti
coliti
forth
may
dissemin
involv
organ
system
caus
significantli
higher
mortal
detect
adenoviru
blood
may
preced
symptomat
diseas
week
provid
opportun
preemptiv
intervent
howev
identif
patient
might
benefit
therapi
remain
challeng
exampl
retrospect
studi
pediatr
hsct
recipi
show
patient
diagnos
adenoviru
infect
clear
viru
without
antivir
therapi
coinfect
sequenti
infect
multipl
serotyp
demonstr
pediatr
hsct
recipi
individu
may
prolong
viral
excret
adenoviru
infect
typic
occur
within
first
month
solidorgan
transplant
predilect
involv
allograft
clinic
manifest
liver
infect
includ
jaundic
hepat
lung
infect
present
oblit
bronchiol
respiratori
failur
cardiac
infect
lead
coronari
vasculopathi
renal
infect
present
mainli
hemorrhag
cystiti
may
complic
pneumonia
intestin
infect
present
diarrhea
situat
sever
adenoviru
infect
may
lead
prematur
graft
loss
death
risk
factor
adenovir
infect
includ
younger
age
particularli
children
year
old
intestin
transplant
augment
immun
suppress
includ
antilymphocyt
antibodi
transplant
seroposit
organ
seroneg
recipi
addit
older
seri
incid
adult
liver
transplant
patient
patient
symptomat
diseas
vari
sever
recent
studi
use
pcr
detect
also
shown
asymptomat
infect
blood
adult
solidorgan
transplant
recipi
common
howev
case
associ
progress
diseas
acut
graft
reject
reason
routin
screen
recommend
molecular
detect
adenoviru
blood
affect
tissu
sampl
indic
adult
solidorgan
transplant
recipi
compat
diseas
manifest
convers
pediatr
solidorgan
recipi
serial
monitor
viral
load
blood
may
preced
develop
symptomat
diseas
serv
use
guid
initi
antivir
therapi
current
specif
measur
prevent
adenoviru
infect
transplant
recipi
patient
congenit
immun
defici
prone
infect
wide
array
microb
bacteri
fungal
viral
forth
includ
adenoviru
exceedingli
rare
natur
inherit
disord
true
incid
adenovir
diseas
known
adenoviru
infect
commonli
describ
sever
congenit
immun
defici
scid
condit
cellular
humor
immun
defect
adenovir
diseas
scid
may
involv
organ
system
rapidli
fatal
addit
higher
incid
unusu
serotyp
patient
compar
immunocompet
children
develop
highli
activ
antiretrovir
therapi
haart
patient
infect
hiv
adenoviru
infect
frequent
detect
associ
sever
opportunist
pathogen
despit
potenti
confound
effect
multipl
coinfect
variou
case
report
describ
sever
pneumonia
hepat
meningoenceph
nephriti
gastrointestin
potenti
fatal
dissemin
diseas
caus
adenoviru
comprehens
review
estim
patient
clinic
aid
develop
activ
adenoviru
infect
studi
mean
age
patient
year
within
month
first
detect
adenoviru
associ
mortal
remark
aspect
adenoviru
infect
aid
divers
serotyp
frequenc
lee
qureshi
antigen
intermedi
isol
presum
aris
spontan
mutat
within
strain
recombin
coinfect
serotyp
longterm
infect
clarifi
epidemiolog
adenoviru
infect
patient
infect
hiv
prospect
longitudin
studi
subsequ
perform
determin
actuari
incid
adenoviru
infect
count
greater
mm
count
less
mm
prolong
gener
asymptomat
shed
gastrointestin
tract
lesser
degre
urinari
tract
document
patient
data
suggest
mortal
rate
adenoviru
infect
aid
may
lower
previous
state
howev
differ
patient
popul
adenoviru
detect
method
preclud
definit
conclus
true
attribut
mortal
nonetheless
absenc
anoth
plausibl
explan
adenoviru
infect
consid
potenti
caus
agent
critic
ill
patient
infect
hiv
sever
pneumonia
enceph
hepat
high
retrovir
load
andor
cell
count
less
mm
addit
exclus
bacteri
atyp
organ
main
differenti
diagnosi
sever
viral
pneumonia
immunocompet
host
includ
influenza
parainfluenza
rsv
follow
sever
less
common
agent
measl
varicella
rhinoviru
other
immunocompromis
host
reactiv
member
herpesviru
famili
cytomegaloviru
cmv
epsteinbarr
viru
ebv
human
herpesviru
well
adenoviru
also
consid
differenti
diagnosi
lifethreaten
pneumonia
meningoenceph
case
dissemin
organ
dysfunct
case
adequ
sampl
procur
potenti
infect
site
requir
analysi
sever
respiratori
failur
nasopharyng
aspir
endotrach
secret
bronchoalveolar
lavag
suitabl
rel
easi
obtain
viral
microbiolog
studi
comprehens
analysi
lung
tissu
also
extrem
valuabl
transbronchi
surgic
biopsi
perform
dissemin
diseas
suspect
blood
sampl
also
obtain
detect
circul
adenoviru
recent
gold
standard
diagnosi
adenovir
diseas
clinic
sampl
identif
characterist
cytopath
effect
use
tissu
culturebas
method
howev
approach
slow
costli
technic
challeng
may
lack
sensit
direct
antigen
detect
respiratori
specimen
immunofluoresc
relat
techniqu
rapid
less
sensit
altern
viral
isol
serolog
determin
antibodi
respons
viral
serotyp
genotyp
method
impract
use
clinic
decis
make
mainli
use
epidemiolog
investig
techniqu
supplant
molecular
detect
method
appli
blood
stool
sputum
biopsi
specimen
qualit
pcr
quantit
realtim
pcr
rapid
highli
sensit
techniqu
howev
critic
depend
design
primer
probe
abl
amplifi
detect
genom
clinic
relev
adenovirus
amplif
highli
conserv
adenoviru
hexon
gene
sequenc
use
multipl
primerprob
combin
singl
assay
success
use
sever
investig
identifi
diseaseassoci
serotyp
medic
center
may
choos
establish
local
pcr
protocol
adenoviru
detect
refer
sampl
commerci
laboratori
servic
provid
regardless
adenoviru
pcr
test
done
essenti
know
sensit
specif
test
protocol
type
clinic
sampl
analyz
addit
confirm
diagnosi
sever
clinic
diseas
mani
bone
marrow
transplant
center
use
weekli
quantit
pcr
monitor
dna
load
adenoviru
well
cmv
ebv
mucos
site
blood
stem
cell
transplant
posit
viral
identif
mucos
site
absenc
clinic
laboratori
abnorm
consist
infect
necessarili
signifi
diseas
hand
adenoviru
detect
site
multipl
occas
multipl
site
predict
diseas
risk
death
suggest
detect
adenoviru
blood
stem
cell
transplant
patient
defin
probabl
dissemin
diseas
may
signifi
window
opportun
earli
intervent
one
approach
use
serial
analysi
viral
load
therapeut
decis
make
pediatr
stem
cell
transplant
patient
recent
publish
howev
known
whether
strategi
applic
adult
decreas
viral
copi
number
may
use
surrog
respons
therapi
convers
titer
greater
ml
associ
greater
likelihood
death
use
earli
intervent
stem
cell
transplant
support
anoth
seri
delay
initi
cidofovir
seem
associ
poor
outcom
manag
option
sever
adenovir
diseas
limit
formal
approv
antivir
agent
proven
efficaci
prospect
random
trial
antiadenovir
therapi
sever
studi
correl
clinic
recoveri
return
cell
therefor
reduct
immun
suppress
gener
recommend
soon
diagnosi
adenoviru
infect
establish
varieti
differ
antivir
agent
includ
ribavirin
ganciclovir
cidofovir
use
treat
adenoviru
infect
howev
none
compound
shown
particularli
efficaci
establish
diseas
cidofovir
acycl
analogu
deoxycytidin
monophosph
vitro
activ
sever
dna
virus
approv
treatment
cmv
retin
poor
bioavail
cidofovir
must
given
intraven
convert
host
enzym
activ
diphosph
form
prolong
intracellular
halflif
cidofovir
diphosph
exhibit
higher
bind
affin
viral
dna
polymeras
compar
host
cell
enzym
inhibit
viral
replic
compet
host
nucleotid
incorpor
viral
dna
common
dose
regimen
mgkg
intraven
weekli
week
everi
week
appropri
clinic
respons
observ
cidofovir
filter
activ
secret
proxim
tubul
kidney
drug
excret
unchang
urin
dosedepend
nephrotox
major
advers
effect
cidofovir
present
proteinuria
azotemia
glycosuria
metabol
acidosi
uncommonli
fanconi
syndrom
salin
prehydr
administr
probenecid
recommend
mitig
cidofovir
toxic
dose
adjust
discontinu
cidofovir
recommend
case
increas
creatinin
level
proteinuria
lipid
analogu
hexadecyloxypropylcidofovir
exhibit
much
better
cellular
penetr
greater
vitro
activ
adenoviru
shown
promis
result
immunesuppress
anim
model
dissemin
diseas
ribavirin
guanosin
analogu
use
treat
sever
rsv
pneumonia
shown
consist
clinic
benefit
efficaci
varieti
sever
adenoviru
infect
recommend
similarli
ganciclovir
show
vitro
activ
adenoviru
isol
report
reduc
incid
infect
stem
cell
transplant
howev
insuffici
clinic
experi
support
use
variou
strategi
immun
reconstitut
host
current
investig
yet
wide
avail
exampl
donor
lymphocyt
infus
associ
temporari
clearanc
adenoviru
howev
approach
current
limit
risk
exacerb
graftversushost
diseas
gvhd
anoth
approach
effect
prevent
treat
diseas
relat
ebv
cmv
reactiv
hsct
recipi
reconstitut
host
vitro
expand
virusspecif
cytotox
lymphocyt
ctl
widespread
applic
strategi
definit
cure
adenoviru
infect
limit
incomplet
knowledg
antigenspecif
tcell
immun
well
practic
technic
regulatori
financi
barrier
gener
suffici
subgroup
crossreact
adenovirusspecif
cytotox
lymphocyt
ex
vivo
novel
tcell
epitop
hexon
protein
recent
identifi
may
lead
improv
adopt
immunotherapi
strategi
futur
intraven
immunoglobulin
use
treat
sever
adenoviru
infect
howev
role
current
undefin
genu
hantaviru
includ
divers
group
spheric
envelop
virus
triseg
negativesens
singlestrand
rna
genom
individu
viral
strain
maintain
prolong
asymptomat
infect
specif
rodent
host
distribut
human
diseas
depend
local
ecolog
circumst
outsid
north
america
varieti
hantavirus
hantaan
viru
known
caus
seriou
fatal
acut
diseas
term
hemorrhag
fever
renal
syndrom
north
america
relat
sin
nombr
viru
snv
common
caus
hantaviru
cardiopulmonari
syndrom
acut
condit
character
sever
respiratori
failur
shock
mild
renal
dysfunct
south
america
and
viru
caus
similar
condit
hantaviru
associ
person
person
transmiss
zoonot
transmiss
snv
relat
strain
occur
domest
occup
exposur
aerosol
infect
rodent
excreta
like
rodent
popul
abund
enter
build
search
food
cover
first
outbreak
north
american
hantaviru
pulmonari
syndrom
describ
four
corner
region
unit
state
subsequ
outbreak
episod
attribut
higher
rodent
densiti
greater
human
exposur
result
increas
precipit
clinic
patholog
featur
clinic
manifest
hantaviru
infect
follow
long
incub
period
day
character
prodrom
fever
chill
myalgia
gastrointestin
symptom
mild
cough
dyspnea
develop
sever
day
associ
mild
pulmonari
diseas
onethird
case
hand
patient
rapidli
develop
sever
respiratori
distress
profound
oxygen
desatur
progress
radiograph
evid
noncardiogen
pulmonari
edema
physic
find
time
present
usual
nonspecif
includ
fever
tachypnea
tachycardia
inspiratori
crackl
mild
hypotens
laboratori
studi
reveal
hemoconcentr
mild
thrombocytopenia
left
shift
circul
myeloblast
circul
immunoblast
mildli
abnorm
liver
function
test
dizzi
nausea
vomit
absenc
cough
present
well
thrombocytopenia
increas
viral
pneumonia
hematocrit
decreas
serum
bicarbon
level
help
distinguish
hantaviru
pulmonari
syndrom
hp
common
caus
acut
respiratori
distress
pneumococc
pneumonia
influenza
sever
case
hemodynam
analysi
consist
shock
state
attribut
combin
fluid
redistribut
myocardi
depress
outcom
hp
unpredict
vari
wide
seri
patient
mild
clinic
cours
surviv
wherea
mortal
fulmin
diseas
high
fatal
case
hp
histopatholog
analysi
show
interstiti
pneumon
variabl
mononuclear
cell
infiltr
edema
focal
hyalin
membran
remaind
diffus
alveolar
damag
variabl
degre
sever
airspac
disorgan
immunohistochemistri
electron
microscopi
demonstr
widespread
presenc
hantaviru
antigen
viral
inclus
pulmonari
microvascular
endotheli
cell
well
dendrit
cell
macrophag
lymphocyt
sever
clinic
diseas
immunopatholog
respons
implic
pathogenesi
capillari
leak
syndrom
result
sever
pulmonari
edema
hp
extrem
rare
diseas
north
america
less
case
report
unit
state
histor
inform
recent
travel
rural
area
endem
hantaviru
infect
andor
exposur
potenti
infect
rodent
may
enter
human
dwell
crucial
initi
consider
patient
present
sever
hantaviru
infect
invari
detect
humor
immun
respons
posit
serolog
test
igm
igg
diagnost
diseas
lowpreval
geograph
area
viremia
occur
first
day
ill
may
detect
rtpcr
blood
howev
isol
hantaviru
requir
appropri
contain
facil
practic
diagnost
purpos
mainstay
clinic
manag
hp
excel
support
care
particular
attent
care
manag
fluid
statu
minim
alveolar
edema
maintain
overal
organ
perfus
use
rescu
therapi
steroid
extracorpor
life
support
potenti
benefit
howev
administr
ribavirin
shown
efficaci
snv
despit
vitro
activ
hantaviru
prevent
human
hantaviru
infect
includ
environment
ecolog
measur
control
reduc
exposur
rodent
reservoir
